• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

May 26, 2016

View Archived Issues

One-shot brain delivery leads to diabetes remission, study shows

A single injection of the peptide hormone fibroblast growth factor 1 (FGF1) directly into the brain induced long-term remission from type 2 diabetes in rats and mice. Read More

Seattle Genetics launches pivotal phase III for CD33-targeted ADC

Seattle Genetics Inc. (Seagen) started its second-ever phase III study, pitting a CD33-targeted antibody-drug conjugate paired with widely used hypomethylating agents (HMA) vs. HMAs alone in older patients with newly diagnosed acute myeloid leukemia (AML). Read More

Crossovers bridge to IPO: Selecta sizes $75M hope as Sanofi canopy widens

Eight months after its $38 million series E round brought aboard new strategic and crossover investors, Selecta Biosciences Inc. made manifest what the move often signals, filing for an IPO that would raise as much as $75 million. Read More

Innocoll’s collagen implant hits endpoints in postoperative pain

Shares of Innocoll Holdings plc jumped 47.8 percent Wednesday on word that two phase III trials testing Xaracoll, its long-acting bupivacaine implant, solidly hit their primary endpoints in a postoperative pain study, findings that bode well for the company’s overall collagen-matrix platform technology, even if analysts await greater clarity to gauge the product’s potential in the non-opioid analgesic market. Read More

China’s Precision Med Cloud launched to foster $10B initiative

HONG KONG – Data infrastructure building has started quickly after China’s government announced plans to pour billions into the development of precision medicines. A group of leading companies in cloud computing, medical services and genomics have come together to provide the country with a platform essential to the future bloom of precision medicine in the country. Read More

Sanofi moves to oust Medivation board

DUBLIN – Sanofi SA ratcheted up the tension in its takeover battle with Medivation Inc. by seeking to oust the Medivation board and replace it with its own slate of candidates. It disclosed Wednesday that it had filed preliminary consent solicitation materials with the Securities and Exchange Commission (SEC) in a bid to replace Medivation’s directors with what it described as “eight independent and highly-qualified candidates who are willing to fully and fairly evaluate all of Medivation’s strategic options.” San Francisco-based Medivation quickly responded by unveiling plans to file consent revocation materials with the SEC. Read More

Other news to note

Twoxar Inc., of Palo Alto, Calif., said it is collaborating with the Department of Medicine at the University of Chicago to identify and investigate potential new medicines to treat atherosclerosis. Read More

Financings

Appili Therapeutics Inc., of Halifax, Nova Scotia, said it raised about C$3.3 million (US$2.5 million) to advance research and development of its anti-infective candidates and to open a medicinal chemistry lab in Halifax. Read More

In the clinic

Flex Pharma Inc., of Boston, initiated a human proof-of-concept efficacy study in nocturnal leg cramps with its chemically synthesized, single molecule, transient receptor potential ion channel activator, formulated as an orally disintegrating tablet. The randomized, blind, controlled, cross-over study is designed to evaluate the safety and efficacy of its single agent in more than 50 subjects who suffer from nocturnal leg cramps on a frequent basis. Nocturnal leg cramps can cause severe pain, interrupted sleep, reduced quality of life and interference with activities of daily living. The company estimates that NLC affects more than 4 million Americans nightly. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 8, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 8, 2025.
  • U.S. Capitol building, Washington D.C.

    House passes H.R. 1, restoring R&D tax cuts

    BioWorld MedTech
    The House of Representatives passed H.R. 1, also known as One Big Beautiful Bill, which will restore personal income tax cuts that expired in 2022. However, the...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe